ALK and lung cancer: It can be assumed that the number of ALK-positive patients included in the original Lung-molGPA study is of a similar size as in our study, taking into account the duration for which the patients received treatment, the available molecular diagnostic assessment at that time and the percentage of ALK-positive lung cancer in a cohort of nonsmall cell lung cancer patients.